BeyondSpring, Inc. Banner Image

BeyondSpring, Inc. has reached its limit for free report views

Work for BeyondSpring, Inc.? Upgrade Your Profile and unlock all your annual reports.

BeyondSpring, Inc.

  • Ticker BYSI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BeyondSpring, Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medicalMore needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway.
BeyondSpring, Inc.

Most Recent Annual Report

BeyondSpring, Inc. MOST RECENT 2020 Annual Report

Report Locked. BeyondSpring, Inc. has reached its limit for free report views.

Older/Archived Annual Reports